Cowen and Company’s Gilead Sciences GILD Stock Holding History

Cowen and Company’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,222	Closed	-$166K	–	422
2020 Q1	$166K	Buy	+2,222	New	+$154K	0.04%	207

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cowen and Company's GILD Position: Q2 2020 in Review

Cowen and Company sold out of Gilead Sciences (GILD) in Q2 2020, closing a stake of 2,222 shares — an estimated $166K sold.

Cowen and Company first reported a position in GILD in Q1 2020 and held it in 1 quarter. The position peaked at $166K in Q1 2020. 1,626 funds tracked by Wall St. Rank hold GILD as of Q2 2020.

Cowen and Company reported no remaining Gilead Sciences position as of Q2 2020 after selling out during the quarter.
Cowen and Company sold 2,222 Gilead Sciences shares in Q2 2020, an estimated $166K.
Cowen and Company first reported a position in Gilead Sciences in Q1 2020 and held it in 1 quarter.
Cowen and Company's Gilead Sciences position peaked at $166K in Q1 2020.
1,626 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2020.

Based on Cowen and Company's 13F filing for Q2 2020, filed 13 Aug 2020.